Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis

Journal of Hypertension

Volumn 33, Issue 10, 2015, Pages 2165-2172

  Rakugi, Hiromi ^a   Ogihara, Toshio ^b   Saruta, Takao ^c   Kawai, Tatsuo ^a   Saito, Ikuo ^c   Teramukai, Satoshi ^d   Shimada, Kazuyuki ^e   Katayama, Shigehiro ^f   Higaki, Jitsuo ^g   Odawara, Masato ^h   Tanahashi, Norio ^f   Kimura, Genjiroh ⁱ  

^a OSAKA UNIVERSITY   (Japan)

^b MORINOMIYA UNIVERSITY OF MEDICAL SCIENCES   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e Shin Oyama City Hospital   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h TOKYO MEDICAL UNIVERSITY   (Japan)

ⁱ Asahi Rousai Hospital   (Japan)

Author keywords

angiotensin II receptor blocker; calcium channel blocker; combination therapy; diuretics; elderly hypertension; isolated systolic hypertension; visit to visit variability of blood pressure

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; OLMESARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY; AGE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; RISK FACTORS; TETRAZOLES;

EID: 84960155408     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000668     Document Type: Article

References (29)

1. Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers TC. Drug treatment of hypertension in the elderly: a meta-Analysis. Ann Intern Med 1994; 121:355-362.
2. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al., Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37:253-387.
3. Mancia G1, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al., Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
4. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
5. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al., ACCOMPLISH Trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
6. Ogihara T, Matsuzaki M, Umemoto S, Rakugi H, Matsuoka H, Shimada K, et al., Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Combination therapy for hypertension in the elderly: a sub-Analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res 2012; 35:441-448.
7. Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med 2012; 125:981-990.
8. Ogihara T, Saruta T, Rakugi H, Shimamoto K, Ito S, Matsuoka H, et al., the COLM study investigators. Rationale, study design and implementation of the COLM study: the Combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients. Hypertens Res 2009; 32:163-167.
9. Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, et al., Teramukai S. for the COLM investigators. Combination of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens 2014; 32:2054-2063.
10. Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, et al., COLM Investigators. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. Hypertens Res 2015; 38:89-96.
11. Kawai T, Ohishi M, Kamide K, Onishi M, Takeya Y, Tatara Y, et al. The impact of visit-To-visit variability in blood pressure on renal function. Hypertens Res 2012; 35:239-243.
12. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375:938-948.
13. Rothwell PM, Howard SC, Dolan E, Obrien E, Dobson JE, Dahlöf B, et al. Prognostic significance of visit-To-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375:895-905.
14. Kawai T, Ohishi M, Ito N, Onishi M, Takeya Y, Yamamoto K, et al. Alteration of vascular function is an important factor in the correlation between visit-To-visit blood pressure variability and cardiovascular disease. J Hypertens 2013; 31:1387-1395.
15. Muntner P, Levitan EB, Lynch AI, Simpson LM, Whittle J, Davis BR, et al. Effect of chlorthalidone, amlodipine, and lisinopril on visit-To-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) 2014; 16:323-330.
16. Ueda K, Omae T, Hasuo Y, Kiyohara Y, Fujii I, Wada J, et al. Prognosis and outcome of elderly hypertensives in a Japanese community: results from a long-Term prospective study. J Hypertens 1988; 6:991-997.
17. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-Analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
18. Okayama A, Kadowaki T, Okamura T, Hayakawa T, Ueshima H, NIPPON DATA80 Research Group. Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese men (NIPPON DATA80). J Hypertens 2006; 24:459-462.
19. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al., Bulpitt CJ, HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898.
20. Rothwell PM. Does blood pressure variability modulate cardiovascular risk? Curr Hypertens Rep 2011; 13:177-186.
21. Rothwell PM, Howard SC, Dolan E, Obrien E, Dobson JE, Dahlöf B, et al., ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9:469-480.
22. Webb AJ, Fischer U, Rothwell PM. Effects of b-blocker selectivity on blood pressure variability and stroke: a systematic review. Neurology 2011; 77:731-737.
23. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensivedrug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-Analysis. Lancet 2010; 375:906-915.
24. Webb AJ, Rothwell PM. Effect of dose and combination of antihypertensives on interindividual blood pressure variability: a systematic review. Stroke 2011; 42:2860-2865.
25. Matsui Y, Orourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-Day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension 2012; 59:1132-1138.
26. Chowdhury EK, Owen A, Krum H, Wing LM, Nelson MR, Reid CM, Second Australian National Blood Pressure Study Management Committee. Systolic blood pressure variability is an important predictor of cardiovascular outcomes in elderly hypertensive patients. J Hypertens 2014; 32:525-533.
27. Brickman AM, Reitz C, Luchsinger JA, Manly JJ, Schupf N, Muraskin J, et al. Long-Term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol 2010; 67:564-569.
28. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-To-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension 2011; 57:160-166.
29. Matsui Y, Eguchi K, Orourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54:716-723.